Related references
Note: Only part of the references are listed.Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid
Charles S. Cleeland et al.
CANCER (2013)
Reducing the burden of bone metastases
Roger von Moos et al.
SUPPORTIVE CARE IN CANCER (2013)
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid
S. Vadhan-Raj et al.
ANNALS OF ONCOLOGY (2012)
Mining electronic health records: towards better research applications and clinical care
Peter B. Jensen et al.
NATURE REVIEWS GENETICS (2012)
Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)
Mellissa Yong et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)
Mette Norgaard et al.
JOURNAL OF UROLOGY (2010)
Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer
Joanne E. Mortimer et al.
SEMINARS IN ONCOLOGY (2010)
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases - Analysis of a national medical claims database
Hind T. Hatoum et al.
CANCER (2008)
Economic burden of metastatic bone disease in the US
Kathy L. Schulman et al.
CANCER (2007)
Clinical features of metastatic bone disease and risk of skeletal morbidity
Robert E. Coleman
CLINICAL CANCER RESEARCH (2006)
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
F Saad et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions
KP Weinfurt et al.
MEDICAL CARE (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
The new bisphosphonate, Zometa((R)) (Zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate
A Lipton et al.
CANCER INVESTIGATION (2002)
Share Paper
